Armistice Capital is a global, value-oriented and event-driven hedge fund focused primarily on the health care and consumer sector.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 5, 2022
Karyopharm Therapeutics
|
Post-IPO Equity | $165M | Health Care | — |
Jul 7, 2022
Provention Bio
|
Post-IPO Equity | $60M | Biotechnology | Yes |
Mar 4, 2022
Eyenovia
|
Post-IPO Equity | $15M | Biotechnology | Yes |
Sep 24, 2021
Mauna Kea Technologies
|
Post-IPO Equity | €12.50M | Biotechnology | — |